Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VTVT
stocks logo

VTVT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
--
--
-1.057
+92.12%
--
--
-0.910
+18.18%
Estimates Revision
The market is revising No Change the revenue expectations for vTv Therapeutics Inc. (VTVT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 49.48%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+49.48%
In Past 3 Month
Wall Street analysts forecast VTVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTVT is 38.00 USD with a low forecast of 36.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast VTVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTVT is 38.00 USD with a low forecast of 36.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 27.370
sliders
Low
36.00
Averages
38.00
High
40.00
Current: 27.370
sliders
Low
36.00
Averages
38.00
High
40.00
BTIG
NULL -> Buy
initiated
$40
2025-11-18
Reason
BTIG
Price Target
$40
2025-11-18
initiated
NULL -> Buy
Reason
BTIG initiated coverage of vTv Therapeutics with a Buy rating and $40 price target. vTv is a clinical-stage biotech company developing oral drugs for metabolic and inflammatory diseases, the analyst tells investors in a research note. The firm expects the company's lead candidate cadisegliatin, a liver selective glucokinase activator in type 1 diabetes, to reduce hypoglycemic events in the Phase 3 CATT1 trial. It projects over $500M in peak sales for cadisegliatin.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Initiates
$36
2025-04-09
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$36
2025-04-09
Initiates
Strong Buy
Reason
Alliance Global Partners
James Molloy
Strong Buy
Initiates
$35
2024-12-09
Reason
Alliance Global Partners
James Molloy
Price Target
$35
2024-12-09
Initiates
Strong Buy
Reason
Alliance Global Partners analyst James Molloy initiated coverage of vTv Therapeutics with a Buy rating and $35 price target. vTv is a clinical-stage pharmaceutical company focused on developing treatment options for metabolic and inflammatory diseases, primarily targeting type 1 diabetes, the analyst tells investors in a research note. The firm says cadisegliatin's mechanism of action allows for liver function restoration.
See All Ratings

Valuation Metrics

The current forward P/E ratio for vTv Therapeutics Inc (VTVT.O) is -7.45, compared to its 5-year average forward P/E of -3.31. For a more detailed relative valuation and DCF analysis to assess vTv Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.31
Current PE
-7.45
Overvalued PE
0.23
Undervalued PE
-6.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.27
Undervalued EV/EBITDA
-0.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
28.23
Current PS
0.00
Overvalued PS
69.75
Undervalued PS
-13.29
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

VTVT News & Events

Events Timeline

(ET)
2025-11-06
17:26:18
vTv Therapeutics Announces Q3 Earnings Per Share of $1.08, Exceeding Consensus Estimate of 98 Cents
select
2025-10-09 (ET)
2025-10-09
08:06:38
vTv Therapeutics Names Three New Members to Scientific Advisory Board
select
2025-09-02 (ET)
2025-09-02
08:27:06
vTv Therapeutics reveals $80 million private placement deal
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-12NASDAQ.COM
Everything You Should Know About vTv Therapeutics (VTVT) Upgrade to Buy Rating

  • vTv Therapeutics Upgrade: vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.

  • Earnings Estimates Impact: The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements, particularly influenced by institutional investors.

  • Zacks Rank System: The Zacks Rank system classifies stocks based on earnings estimate revisions, with only the top 20% receiving a "Strong Buy" or "Buy" rating, suggesting vTv Therapeutics is positioned for potential market-beating returns.

  • Analyst Consensus: Over the past three months, analysts have raised their earnings estimates for vTv Therapeutics by 6.2%, reflecting an improving business trend that could lead to higher stock prices.

[object Object]
Preview
8.5
10-04SeekingAlpha
vTv Therapeutics Files for Resale of 15.9 Million Class A Shares

  • Share Registration: vTv Therapeutics registered 15.88 million Class A common shares for resale by selling stockholders, including 2.13 million outstanding shares and additional shares from warrants.

  • Warrant Details: The registered shares include 8.47 million shares from pre-funded warrants and 5.27 million shares from common warrants, originating from various agreements and private placements.

  • Proceeds Information: vTv Therapeutics will not receive any proceeds from the resale of shares by the selling stockholders.

  • Recent Developments: The company recently announced an $80 million PIPE financing, which resulted in a 14% increase in its share price.

[object Object]
Preview
1.0
09-15Newsfilter
vTv Therapeutics to Take Part in INNODIA Symposium During EASD 61st Annual Meeting

  • vTv Therapeutics Presentation: vTv Therapeutics Inc. will present investigational small molecules for type 1 diabetes at the INNODIA Symposium during the EASD Annual Meeting, highlighting preclinical data on TTP-RA and updates on cadisegliatin.

  • Focus on Diabetes Treatment: TTP-RA, an oral RAGE antagonist, aims to prevent T1D, while cadisegliatin is being studied as a potential first-in-class oral adjunctive therapy for T1D, currently in Phase 3 trials.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is vTv Therapeutics Inc (VTVT) stock price today?

The current price of VTVT is 27.37 USD — it has increased 5.84 % in the last trading day.

arrow icon

What is vTv Therapeutics Inc (VTVT)'s business?

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

arrow icon

What is the price predicton of VTVT Stock?

Wall Street analysts forecast VTVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTVT is 38.00 USD with a low forecast of 36.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is vTv Therapeutics Inc (VTVT)'s revenue for the last quarter?

vTv Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is vTv Therapeutics Inc (VTVT)'s earnings per share (EPS) for the last quarter?

vTv Therapeutics Inc. EPS for the last quarter amounts to -1.08 USD, increased 22.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for vTv Therapeutics Inc (VTVT)'s fundamentals?

The market is revising No Change the revenue expectations for vTv Therapeutics Inc. (VTVT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 49.48%.
arrow icon

How many employees does vTv Therapeutics Inc (VTVT). have?

vTv Therapeutics Inc (VTVT) has 23 emplpoyees as of December 05 2025.

arrow icon

What is vTv Therapeutics Inc (VTVT) market cap?

Today VTVT has the market capitalization of 107.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free